Botanicals and chronic diseases: Presentation summary

Abstract

Pharmacologically active phytochemicals (botanical therapeutics) have been used historically to treat and prevent diseases. In the US, botanical therapeutics can be developed as food additives, dietary supplements, and drugs containing a single plant-derived bioactive or mixture of bioactives. Conventional approaches to drug discovery from plants, based on ethical bioprospecting, high throughput screening, and computer-assisted drug design have limitations that have restricted botanical therapeutics research in the pharmaceutical and food industries. In addition, biopiracy concerns, extract standardization, batch-to-batch consistency, proper botanical vouchering and identification of actives have curtailed the development and sales of multicomponent botanical therapeutics. Fortunately, novel enabling technologies and favorable regulatory changes are making the discovery and development of botanical therapeutics more efficient and less controversial. These technologies are leading to the development of novel, safe, and efficacious botanical therapeutics for major human diseases. The past, present, and future of botanical therapeutic research will be discussed as well as specific examples of recently developed products for inflammation and metabolic syndromes.

Keywords::

• Botanical drugs
• chronic diseases
• standardization
• Tripterygium wilfordii
• Artemisia dracunculus
• bioprospecting

Acknowledgements

This article was presented at the Symposium: “Plants in the Service of Human Health: Continuing Search for Plant-based Therapies” – Society for Economic Botany 48th Annual Meeting in Chicago at Lake Forest College, June 4, 2007.

This article is a summary based on the presentation of Dr. Ilya Raskin of the Biotech Center, Rutgers University, New Brunswick, NJ, written by Dr. Charlotte Gyllenhaal. The Proceedings Editors were provided the full PowerPoint presentation by Dr. Ilya Raskin

Declaration of interest: The author reports no conflicts of interest.